Bronchial asthma: simple solutions of complex issues
https://doi.org/10.21518/2079-701X-2019-6-52-57
Abstract
The problem of achieving control of bronchial asthma (BA), regardless of severity, remains relevant. The use of extra-finely dispersed Beclomethasone/Formoterol FC (EMB FC BDP/FOR) according to the concept of Maintenance and Reliever Therapy (MART) has clinical advantages over traditional basal therapy in combination with symptomatic drugs. In the studies, BA Phenotypes for the use of EMD-FC BDP/FOR: BA in smoking patients, asthma with hyperinflation and asthma in older people and with a disease duration of more than 10 years were established. Clinical cases of treatment of EMD FC BDP/FOR are presented in accordance with the MART concept in older patients with uncontrolled asthma on the background of comorbidities and persistent bronchial obstruction, which have a positive effect and controlled asthma.
About the Authors
I. V. Leshchenko
Federal State Budgetary Educational Institution of Higher Education «Urals State Medical University» of the Ministry of Healthcare of the Russian Federation;
LLC Medical Association New Hospital
Russian Federation
Russian Federation
Leshchenko Igor Viktorovich – Dr. of Sci. (Med), Professor of the Department of Phthisiology, Pulmonology and Thoracic Surgery of the Federal State Budgetary Educational Institution of Higher Education «Ural State Medical University» of the Ministry of Health of the Russian Federation, Scientific Director of LLC «Medical Association «New Hospital»
620028, Sverdlovsk region, Ekaterinburg, 3 Repina str.,
620109, Ekaterinburg, 29, Zavodskaya str.
I. I. Baranova
Federal State Budgetary Educational Institution of Higher Education «Urals State Medical University» of the Ministry of Healthcare of the Russian Federation;
LLC Medical Association New Hospital
Russian Federation
Russian Federation
Baranova Ilona Igorevna – Candidate of Medical Sciences, Assistant of the Department of Phthisiology, Pulmonology and Thoracic Surgery of the Federal State Budgetary Educational Institution of Higher Education «Ural State Medical University» of the Ministry of Health of the Russian Federation, Pulmonologist of LLC «Medical Association «New Hospital»
620028, Sverdlovsk region, Ekaterinburg, 3 Repina str.,
620109, Ekaterinburg, 29, Zavodskaya str.
References
1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2018. [Электронный ресурс] Available from: http://www.ginasthma.org/.
2. Price D., Fletcher M., van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir. Med 2014;24:14009.
3. Buhl R., Kuna P., Peters M.J. et al. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomized, controlled studies with comparisons to standard therapy. Respir. Res. 2012. doi.org/10.1186/1465-9921-13-59.
4. Suissa S., Ernst P., Boivin J.F. et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am. J. Respir. Crit. Care Med. 1994;149:604-610.
5. Suissa S., Ernst P., Benayoun S. et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 2000;343:332-336.
6. Kuna P., Peters M.J., Manjra A.I. et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int. J. Clin. Pract. 2007;61(5):725–736.
7. Anderson W.J., Zajda E., Lipworth B.J. Are we overlooking persistent small airways dysfunction in community-managed asthma? Ann. Allergy Asthma Immunol. 2012;109:185–189.
8. Fabbri L.M., Nicolini G., Olivieri D., Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opinion Pharmacotherapy. 2008;9(3):479-490.
9. Papi A., Paggiaro P., Nicolini G. et al. ICAT SE study group. Beclomethasone/formoterol vs. fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007;62(10):1182–1188.
10. Foster Summary of Product Characteristics. Chiesi Pharmaceutics S.p.A.
11. Jonkers R.E., Bantje T.A., Aalbers R. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a doubleblind, placebo-controlled study. Resp. Res. 2006;7: 141. https://doi.org/10.1186/1465-9921-7-141.
12. Morjaria J.B., Rigby A.S., Morice A.H. Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma? Eur. Respir. J. 2017;50:1701366. https://doi.org/10.1183/13993003.01366-2017.
13. Papi A., James W., Corrigan C. et al. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomized, double-blind clinical trial. The Lancet Resp. Medicine. 2013;1:23– 31.
14. Marth K., Spinola M., Kisiel J. et al. Treatment response according to small airway phenotypes: a real-life observational study. Ther. Adv. Respir. Dis. 2016;10(3):200–210.
15. Hsieh M.J., Lin Y-C., Lai R-S. et al. Comparative efficacy and tolerability of beclomethasone/ formoterol and fluticasone/salmeterol fixed combination in Taiwanese asthmatic patients. J. Formosan Med. Association. 2017. https://doi.org/10.1016/j.jfma.2017.12.005.
Review
For citations:
Leshchenko IV, Baranova II. Bronchial asthma: simple solutions of complex issues. Meditsinskiy sovet = Medical Council. 2019;(6):52-57. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-52-57
Views:
894
Email this article 